Production (Stage)
CG Oncology, Inc.
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 662.00K | 1.14M | 684.00K | 650.00K | 636.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 662.00K | 1.14M | 684.00K | 650.00K | 636.00K |
| Cost of Revenue | 92.36M | 82.10M | 71.64M | 61.85M | 52.22M |
| Gross Profit | -91.70M | -80.96M | -70.96M | -61.21M | -51.59M |
| SG&A Expenses | 42.70M | 33.70M | 25.01M | 18.79M | 13.58M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 135.06M | 115.81M | 96.66M | 80.64M | 65.80M |
| Operating Income | -134.40M | -114.67M | -95.97M | -80.00M | -65.18M |
| Income Before Tax | -105.56M | -88.04M | -72.80M | -64.00M | -55.24M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -105.56 | -88.04 | -72.80 | -64.00 | -55.24 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -105.56M | -88.04M | -72.80M | -64.00M | -55.24M |
| EBIT | -134.40M | -114.67M | -95.97M | -80.00M | -65.18M |
| EBITDA | -134.35M | -114.63M | -95.94M | -79.98M | -65.16M |
| EPS Basic | -1.50 | -1.41 | -5.30 | -8.93 | -12.22 |
| Normalized Basic EPS | -0.94 | -0.88 | -2.60 | -4.26 | -5.71 |
| EPS Diluted | -1.50 | -1.41 | -5.30 | -8.93 | -12.22 |
| Normalized Diluted EPS | -0.94 | -0.88 | -2.60 | -4.26 | -5.71 |
| Average Basic Shares Outstanding | 279.03M | 249.91M | 186.02M | 122.80M | 60.03M |
| Average Diluted Shares Outstanding | 279.03M | 249.91M | 186.02M | 122.80M | 60.03M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |